Evidence map›Paper›PMID 23382681›Full record

ArticlePLoS pathogens2013

Cyclosporine A impairs nucleotide binding oligomerization domain (Nod1)-mediated innate antibacterial renal defenses in mice and human transplant recipients.

Emilie Tourneur, Sanae Ben Mkaddem, Cécilia Chassin, Marcelle Bens, Jean-Michel Goujon, Nicolas Charles, Christophe Pellefigues, Meryem Aloulou, Alexandre Hertig, Renato C Monteiro and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 47 citations in OpenAlex.

  1. Uropathogen and host responses in pyelonephritis.Nature reviews. Nephrology · 2023
    Review
  2. Review
  3. NOD-like receptors in asthma.Frontiers in immunology · 2022
    Review
  4. Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression".Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Genetic Deletion of NOD1 Prevents Cardiac CaInternational journal of molecular sciences · 2020
    Article
  10. Article
  11. Review
  12. Role of donor macrophages after heart and lung transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Review
  13. Article
  14. Phagocyte Escape ofFrontiers in immunology · 2020
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Emilie TourneurINSERM U773, Centre de Recherche Biomédicale Bichat Beaujon, Université Paris 7-Denis Diderot, Paris, France.
Sanae Ben Mkaddem
Cécilia Chassin
Marcelle Bens
Jean-Michel Goujon
Nicolas Charles
Christophe Pellefigues
Meryem Aloulou
Alexandre Hertig
Renato C Monteiro
Stephen E Girardin
Dana J Philpott
Eric Rondeau
Carole Elbim
Catherine Werts
Alain Vandewalle
Délégation Paris 7 · FRInserm · FRUniversité Paris Cité · FRUniversity of Toronto · CAHôpital Tenon · FRInstitut Pasteur · FRSorbonne Université · FRUniversité de Poitiers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute pyelonephritis (APN), which is mainly caused by uropathogenic Escherichia coli (UPEC), is the most common bacterial complication in renal transplant recipients receiving immunosuppressive treatment. However, it remains unclear how immunosuppressive drugs, such as the calcineurin inhibitor cyclosporine A (CsA), decrease renal resistance to UPEC. Here, we investigated the effects of CsA in host defense against UPEC in an experimental model of APN. We show that CsA-treated mice exhibit impaired production of the chemoattractant chemokines CXCL2 and CXCL1, decreased intrarenal recruitment of neutrophils, and greater susceptibility to UPEC than vehicle-treated mice. Strikingly, renal expression of Toll-like receptor 4 (Tlr4) and nucleotide-binding oligomerization domain 1 (Nod1), neutrophil migration capacity, and phagocytic killing of E. coli were significantly reduced in CsA-treated mice. CsA inhibited lipopolysaccharide (LPS)-induced, Tlr4-mediated production of CXCL2 by epithelial collecting duct cells. In addition, CsA markedly inhibited Nod1 expression in neutrophils, macrophages, and renal dendritic cells. CsA, acting through inhibition of the nuclear factor of activated T-cells (NFATs), also markedly downregulated Nod1 in neutrophils and macrophages. Silencing the NFATc1 isoform mRNA, similar to CsA, downregulated Nod1 expression in macrophages, and administration of the 11R-VIVIT peptide inhibitor of NFATs to mice also reduced neutrophil bacterial phagocytosis and renal resistance to UPEC. Conversely, synthetic Nod1 stimulating agonists given to CsA-treated mice significantly increased renal resistance to UPEC. Renal transplant recipients receiving CsA exhibited similar decrease in NOD1 expression and neutrophil phagocytosis of E. coli. The findings suggest that such mechanism of NFATc1-dependent inhibition of Nod1-mediated innate immune response together with the decrease in Tlr4-mediated production of chemoattractant chemokines caused by CsA may contribute to sensitizing kidney grafts to APN.

Indexed as

Kidney TransplantationAcute DiseaseAnimalsBone Marrow CellsCell MovementChemokinesCyclosporineDendritic CellsDisease Models, AnimalFemaleGene SilencingHumansImmunity, InnateImmunosuppressive AgentsKidneyMacrophagesChemokinesCyclosporineImmunosuppressive AgentsNFATC Transcription FactorsNOD1 protein, humanNod1 Signaling Adaptor Protein

Identifiers

PMID23382681
PMCPMC3561241
OpenAlexW2030383845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.